Skip to main content
. Author manuscript; available in PMC: 2022 Sep 3.
Published in final edited form as: Biochem Pharmacol. 2020 Dec 14;184:114368. doi: 10.1016/j.bcp.2020.114368

Table I.

Assay performance of the PXR agonist screen using Tox21-88 duplicates and Tox21 10K compound collection in triplicate runs.

Active Match Inactive Match Inconclusive (%) Mismatch (%) EC50 Fold* Change
10K Screen 18.55 83.37 17.67 0.40 1.45
Tox21-88 45.79 35.94 15.53 2.75 1.31
*

For each compound with at least one replicate that is not class 4, the standard deviation (SD) of the EC50 values from all replicates was calculated. The SDs were then averaged across these compounds. The EC50 fold was calculated as the inverse log of the average SD.